Protagonist Therapeutics Inc PTGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
Protagonist Therapeutics Reports Granting of Inducement Awards
Johnson & Johnson Gets FDA Approval for Icotyde in Plaque Psoriasis — Update
Trading Information
- Previous Close Price
- $135.26
- Day Range
- $128.00–138.40
- 52-Week Range
- $76.70–160.81
- Bid/Ask
- $127.01 / $164.88
- Shares Outstanding
- 65.27M
- Market Cap
- $8.54B
- Volume/Avg
- 972,945 / 655,564
Key Statistics
- Price/Earnings (Normalized)
- 128.20
- Price/Sales
- 16.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 141
Valuation
Metric | PTGX |
|---|---|
Price/Earnings (Normalized) | 128.20 |
Price/Book Value | 7.94 |
Price/Sales | 16.62 |
Price/Cash Flow | 23.23 |
Price/Earnings
PTGX
Financial Strength
Metric | PTGX |
|---|---|
Quick Ratio | 19.67 |
Current Ratio | 19.85 |
Interest Coverage | — |
Quick Ratio
PTGX
Profitability
Metric | PTGX |
|---|---|
Return on Assets (Normalized) | 48.14% |
Return on Equity (Normalized) | 51.36% |
Return on Invested Capital (Normalized) | 47.29% |
Return on Assets
PTGX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|hc%ymw$ | LOCK|@>>nk | $139B | |||
| Moderna Inc MRNA | LOCK|Gt!@Xp@ | LOCK|D#@ | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|?f^&xN | LOCK|jXN^ | $94B | |||
| argenx SE ADR ARGX | LOCK|bDkt&D | LOCK|#S | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|pH$r&nB | LOCK|mZ | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<tg!k>Z | LOCK|><sw< | $30B | |||
| Incyte Corp INCY | LOCK|z<?<>D | LOCK|hz | $24B | |||
| BioNTech SE ADR BNTX | LOCK|$<n&C!G | LOCK|<! | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|fHHp>$ | LOCK|bz?@% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Kcln>< | LOCK|??S | $15B |
United States